Literature DB >> 16496423

Nine fluorescence parameter analysis on a four-color fluorescence activated flow cytometer.

Ursula Frischmann1, Werner Müller.   

Abstract

BACKGROUND: In many cases a frequent monitoring of blood is important, e.g. during an infection. Often the availability of blood is the limiting factor.
METHODS: 50 microl blood were stained and analyzed using a standard four-color cytometer. Percentages of leukocytes were calculated by FlowJo software.
RESULTS: Our protocol allows the differentiation of B cells, T cells, NK cells, neutrophils, and monocytes/macrophages in small volumes of blood.
CONCLUSIONS: Using nine fluorochrome-labeled antibodies and a specific gating strategy we were able to differentiate the main immune cells in minute amounts using one staining step. (c) 2006 International Society for Analytical Cytology.

Mesh:

Substances:

Year:  2006        PMID: 16496423     DOI: 10.1002/cyto.a.20221

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  4 in total

1.  Dynamic immune cell accumulation during flow-induced atherogenesis in mouse carotid artery: an expanded flow cytometry method.

Authors:  Noah Alberts-Grill; Amir Rezvan; Dong Ju Son; Haiwei Qiu; Chan Woo Kim; Melissa L Kemp; Cornelia M Weyand; Hanjoong Jo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-01-12       Impact factor: 8.311

2.  Innate immune responses in NF-kappaB-repressing factor-deficient mice.

Authors:  Natali Froese; Michael Schwarzer; Ina Niedick; Ursula Frischmann; Mario Köster; Andrea Kröger; Peter P Mueller; Mahtab Nourbakhsh; Bastian Pasche; Jörg Reimann; Peter Staeheli; Hansjörg Hauser
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

3.  Transient receptor potential vanilloid 1 expression and function in splenic dendritic cells: a potential role in immune homeostasis.

Authors:  Mushref Bakri Assas; Majed H Wakid; Haytham A Zakai; Jaleel A Miyan; Joanne L Pennock
Journal:  Immunology       Date:  2016-03       Impact factor: 7.397

4.  XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.

Authors:  Joel G Turner; Trinayan Kashyap; Jana L Dawson; Juan Gomez; Alexis A Bauer; Steven Grant; Yun Dai; Kenneth H Shain; Mark Meads; Yosef Landesman; Daniel M Sullivan
Journal:  Oncotarget       Date:  2016-11-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.